STRENSIQ 40 mg/ml, solution for injection 12 bottles of 1 ml
Active ingredients: Asfotase alfa
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection12 bottles of 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- STRENSIQ 40 mg/ml, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 12 flacon(s) en verre de 1 ml
- Marketing authorisation holder
- ALEXION EUROPE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Jan 2018
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64450234CIP73003114CIP133400930031148Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ASFOTASE ALFAsolution | 40 mg · 1 ml de solution injectable | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.